An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203

NCT02573467 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

211

Enrollment

INDUSTRY

Sponsor class

Conditions

Sporadic Inclusion Body Myositis

Interventions

DRUG: Bimagrumab
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals